Canada: Pharma In Brief - Canada: Section 8: Federal Court Provides Insight Into The Determination Of Damages In The Hypothetical Market

Case: Apotex Inc. v. Takeda Canada Inc., 2013 FC 1237
Drug: Protonix ® (pantoprazole)
Nature of case: Damages action under section 8 of the Patented Medicines (Notice of Compliance) Regulations
Date of decision: December 11, 2013

Summary

On December 11, 2013 the Federal Court released an important decision pertaining to the determination of damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations). This decision provides new insight into the construction of the hypothetical market in which generic damages are assessed. Most striking is the Court's acknowledgment that an innovator could face various section 8 claims that may exceed the total of real losses - a risk the Court dismissed as "the loser's risk." The true impact of this decision will have to await the release of the Federal Court of Appeal's decision in Ramipril (A-191-12), which was heard on October 30, 2013 and remains under reserve.

The issues at trial

This action involved the amount of compensation owed to Apotex for its delayed market entry for Apo-pantoprozole for the period March 9, 2007 to March 5, 2008. The trial judge was not asked to quantify the damages owed by Takeda Canada Inc. (Takeda) to Apotex, but rather to determine the following nine disputed issues which would assist the parties in arriving at the final calculation of damages.

1. Burden

The trial judge held that in constructing the hypothetical market from which Apotex's damages were to be assessed, the Court should "mirror as much as possible real world circumstances" and then "work out what likely would have happened" had the generic not been delayed. The Court rejected "the percentage weight approach" proposed by Apotex. The trial judge reiterated that a section 8 claimant bears the burden of proving its lost sales and the deductions to be made from those sales on a balance of probabilities, while a section 8 defendant bears the burden of proving any affirmative defence, including the presence of other generic competitors in the hypothetical market.

2. Number and identity of generic market entrants

Takeda argued that there would have been three other generic competitors as well as simultaneous entry by its authorized generic, Ranbaxy.

The trial judge considered real world evidence surrounding the motivation and timing of Takeda's decision to launch an authorized generic to determine when this would have occurred in the "but for" world. The Court held that although the approval for Takeda's authorized generic took about a year in the real world, the launch would have occurred 3 months after Apotex's market entry. The Court rejected the suggestion that Ranbaxy was a mere "stalking horse" designed to minimize section 8 damages.

The trial judge also considered whether other generic manufacturers that had served NOAs would have competed with Apotex in the "but for" world. The Court considered real world evidence and noted that Takeda resisted Teva's market entry "at every turn." This led the Court to conclude that Takeda would have asserted its patents against Teva in the "but for" world and that Teva would not have obtained an NOC until close to the hearing date. Other market entrants who settled section 6 proceedings against Takeda were considered to have entered the market as of their patent hold dates consistent with the Court's holding in Apotex Inc. v. Merck & Co., Inc. 2012 FC 1235 (Alendronate).

3. Apotex's market share percentage

This issue revolved around how long it would take Ranbaxy to gain market share upon entry and achieve "steady state" in sales. Apotex had the burden of proof. Experts from both sides presented econometric models, none of which found complete favour with the trial judge. The Court ultimately accepted the evidence of Apotex's expert who applied his "business judgment" to economic "data."

4. Apotex's lost revenue/pricing

Apotex had the burden of proving the formulary price at which Apo-pantoprazole tablets would have been sold in each of the provinces, whether as the sole market entrant or in a competitive market. As with the trial decision in Ramipril and Alendronate, the trial judge rejected as "self-serving" Apotex's evidence that its price would have been 80-90% of the brand price during the sole generic period. Instead, the trial judge relied on evidence from provincial formulary representatives from Ontario, Quebec and Alberta and held that during the period when Apotex was the sole generic market entrant, it would have had a 75% list price in Ontario and Alberta, a 60% list price in Quebec (reflecting its "most favoured nation" policy), and a 70% list price in the rest of Canada. In a competitive market, the trial judge found that Apotex's prices would have dropped to 50% of Takeda's price in Ontario, Newfoundland and Quebec and 63% of Takeda's price in the other provinces.

5. Inventory adjustment

The trial judge considered it appropriate to apply an inventory adjustment to reflect the initial "pipefill" that occurs in the real world, but which is not reflected in IMS data because of the delay inherent in the reporting of ex-factory sales. Since this reporting lag continues until inventory levels reach a steady state, the dispute between the parties' experts centred over the point at which "steady state" or "normalized sales" was achieved which drives the inventory adjustment period. The trial judge considered the methodology adopted by Takeda's expert to make more sense since he weighted the different provincial markets by population. The appropriate adjustment was held to be in the 11-13% range (by way of a reduction to total sales).

6. Double ramp-up

Perhaps one of the most surprising findings in this case was the Court's decision to award "ramp-up" losses to Apotex, a loss squarely rejected by the Federal Court of Appeal in Apotex Inc. v. Merck & Co., Inc. 2009 FCA 187 and the trial decision in Ramipril and Alendronate. The trial judge held that he was not bound by stare decisis or comity, as the previous decisions did not focus on "the economic loss of not being able to ameliorate "ramp up" which occurs in the relevant period and which he was of the view he could consider under subsection 8(5) of the Regulations which permits the Court to take into account all matters that it considers relevant in assessing the amount of compensation owed. The trial judge concluded that it is a proper exercise of its discretion not to include "ramp up" in the relevant period where "ramp up" was experienced in the real world.

7. Rebates

Apotex had the burden of proving what rebates it would have offered in the sole and competitive markets. For the first time, the Court also distinguished between rebates paid to chain pharmacies and those paid to independent (aka banner) pharmacies. Also for the first time, the rebate levels were not redacted from the public version of the decision providing new insight into what has been referred to as a "murky" practice.

The trial judge considered Apotex's evidence that in a sole source market it would have offered little or no rebates to be overstated and self-serving . The trial judge also rejected Takeda's argument that Apotex would have paid the same rebates in a sole and competitive market, as this failed to draw a distinction between the buying power of the various purchasers. The trial judge accepted Apotex's evidence with respect to rebates that would have been paid in a single generic market (8.9%) based on a "comparator drug." The trial judge held that a rebate of 44.7% would have been paid to chains drug stores in a competitive generic market (representing 55% of the market) based on real world experience. The Court applied a "broad axe" approach in determining that Apotex would have paid a 15% rebate to banner pharmacies in the "but for" world.

8. Prejudgment interest

The Court held that Apotex is entitled to simple interest in accordance with Ontario law. Section 127 of the Ontario Courts of Justice Act defines "prejudgment interest rate" as "the bank rate at the end of the first day of the last month of the quarter preceding the quarter in which the proceeding was commenced." That rate was 3.3% which the trial judge applied as of Apotex's patent hold date, being the date the cause of action arose.

9. Discretion to reduce damages

Takeda asked the trial judge to reduce Apotex's damage award on the basis of its breach of an undertaking given in the underlying prohibition proceeding not to market or promote Apo-pantoprazole in combination with one or more Helicobacter inhibiting anti-microbial agents for the treatment of H. pyloric diseases. Takeda argued that Apotex had given this undertaking in order to shield itself from an infringement claim only to breach that undertaking upon its entry into the market. The trial judge agreed that the allegation was grave – amounting to a form of contempt – but he was not prepared to characterize the statements in Apotex's notice of allegation as an undertaking. The Court held that "while statements in an NOA may rise to the level of an undertaking to be relied on by a court, such statements must be clear and unequivocal" and "bare pleadings" in an NOA do not constitute enforceable undertakings.

Conclusion

This decision provides new insight into the construction of the hypothetical market upon which section 8 damages may be calculated. What remains to be seen, however, is whether it will accord with the Federal Court of Appeal's highly anticipated Federal Court of Appeal decision in Ramipril which is expected to weigh in on critical section 8 issues such as "double ramp up" and the generic market entry "in the absence of the Regulations."

Read the decision

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions